Table 1.
Baseline characteristics of 86 children
| Number | Mean | SD | Median | Range | |
|---|---|---|---|---|---|
| Number of patients | 86 | ||||
| Number of observation | 1010 | ||||
| Dose (mg) | 28.6 | 14.01 | 25 | 5–125 | |
| Gender (male/female) | 56/30 | ||||
| Age (year) | 8.38 | 3.78 | 8.35 | 1.1–16.8 | |
| Weight (kg) | 31.93 | 16.75 | 28.8 | 9.4–78.5 | |
| Height (cm) | 130.28 | 25.2 | 129 | 77–181 | |
| BMI | 17.5 | 4.2 | 16.1 | 12.6–44.1 | |
| Type of disease, n (%) | |||||
| AA | 23 | 26.7% | |||
| ALL | 29 | 33.7% | |||
| AML | 22 | 25.6% | |||
| NHL | 5 | 5.8% | |||
| MDS | 4 | 4.7% | |||
| Other | 3 | 3.5% | |||
| POD | 29.7 | 11.7 | 25 | 0–67 | |
| Laboratory test values | |||||
| HB, g/L | 85.49 | 14.63 | 83.35 | 3.1–811 | |
| HCT, % | 24.42 | 2.88 | 24.26 | 22.−95.4 | |
| ALT, U/L | 48.39 | 33.20 | 40.25 | 4–890 | |
| AST, U/L | 36.42 | 18.54 | 31.75 | 2.9–414 | |
| ALB, U/L | 34.98 | 4.68 | 34.83 | 15–371 | |
| Scr, μmoL/L | 27.40 | 12.84 | 25.5 | 4–215 | |
| T-BIL, μmoL/L | 10.11 | 7.21 | 8.58 | 1.6–205.2 | |
| eGFR, mL/min/1.73 m2 | 179.4 | 34.86 | 172.46 | 24.93–377.54 | |
| Co-medication | |||||
| Triazole | |||||
| None | 4 | ||||
| Voriconazole | 61 | ||||
| Itraconazole | 19 | ||||
| Fluconazole | 1 | ||||
| Posaconazole | 6 | ||||
| Phenytoin | 82 | ||||
| Phenobarbital | 49 | ||||
| Calcium channel blocker | |||||
| None | 51 | ||||
| Nifedipine | 32 | ||||
| Amlodipine | 9 | ||||
AA aplastic anemia, ALL acute lymphocytic leukemia, AML acute myeloid leukemia, NHL non-Hodgkin’s lymphoma, MDS myelodysplastic syndrome